Nxera Pharma Co (TSE:4565) Change In Receivables : 円-415 Mil (TTM As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is Nxera Pharma Co Change In Receivables?

Nxera Pharma Co's change in receivables for the quarter that ended in Mar. 2025 was 円1,943 Mil. It means Nxera Pharma Co's Accounts Receivable declined by 円1,943 Mil from Dec. 2024 to Mar. 2025 .

Nxera Pharma Co's change in receivables for the fiscal year that ended in Dec. 2024 was 円-742 Mil. It means Nxera Pharma Co's Accounts Receivable increased by 円742 Mil from Dec. 2023 to Dec. 2024 .

Nxera Pharma Co's Accounts Receivable for the quarter that ended in Mar. 2025 was 円4,462 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Nxera Pharma Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 61.28.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nxera Pharma Co's liquidation value for the three months ended in Mar. 2025 was 円-36,423 Mil.

Nxera Pharma Co Change In Receivables Historical Data

The historical data trend for Nxera Pharma Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Change In Receivables Chart

Nxera Pharma Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

752.00

-799.00

-210.00

1,315.00

-742.00

Nxera Pharma Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															1,943.00	-2,358.00	-	-	1,943.00

Nxera Pharma Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-415 Mil.

Nxera Pharma Co (TSE:4565) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nxera Pharma Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4462	/	6644	*	91
=	61.28

2. In Ben Graham's calculation of liquidation value, Nxera Pharma Co's accounts receivable are only considered to be worth 75% of book value:

Nxera Pharma Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	34465	-	78618	+	0.75 * 4462	+	0.5 * 8767
=	-36,423

Nxera Pharma Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (TSE:4565) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SOLTF:USA

Address

Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052

Website

https://www.nxera.life

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

Nxera Pharma Co Headlines

No Headlines